Dr. Schaider Discusses Drug Resistance for Melanoma

Helmut Schaider, MD
Published: Tuesday, Oct 24, 2017



Helmut Schaider, MD, associate professor, Dermatology Research Centre, the University of Queensland, discusses adaptive drug resistance for patients with melanoma.

According to Schaider, adaptive drug resistance occurs at the beginning of treatment. Drug resistance generally occurs in the first 3 to 6 weeks.

More studies need to be conducted to determine why the cells become resistant to certain treatments, states Schaider.
 
SELECTED
LANGUAGE


Helmut Schaider, MD, associate professor, Dermatology Research Centre, the University of Queensland, discusses adaptive drug resistance for patients with melanoma.

According to Schaider, adaptive drug resistance occurs at the beginning of treatment. Drug resistance generally occurs in the first 3 to 6 weeks.

More studies need to be conducted to determine why the cells become resistant to certain treatments, states Schaider.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x